natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 1 wherein: upon storage of the pharmaceutical composition at 25 °C and 60% RH for a period of 6 months, the EPA has a second peroxide value not greater than 7 Meq/kg or 6 Meq/kg; or 
Farmaceutski pripravak prema zahtjevu 1, naznačen time da nakon skladištenja pripravka na 25 "C i 60% RH kroz period od 6 mjeseci, EPA ima drugu peroksidnu vrijednost ne veću od 7 Meq/kg, ili ne veću od 6 Meq/kg.
the Fc receptor is an FcY receptor; or ii) the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC). 
Fc receptor je FcY receptor; ili ii) efektorska funkcija je citotoksičnost ovisna o protutijelu i stanično-posredovana citotoksičnost (ADCC).
Composition according to claim 19, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Postupak prema bilo kojem od zahtjeva 7 ili 8, naznačen time da je biocid s jednom ili više aldehidnih skupina odabran iz skupine koju čine formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, te je poželjno formaldehid, glutaraldehid ili njihova smjesa.
The compound described in any one of (1) to (22) above or a pharmacologically acceptable salt thereof for use in a method according to (40) above, wherein the disease is hyperlipidemia, dyslipidemia, lipid metabolism abnormality, arteriosclerosis, or type II diabetes mellitus. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
The compound or composition according to any of claims 1 to 9 for use according to claim 10, wherein the disease is Alzheimer's disease, bovine spongiform encephalopathy (BSE), Parkinson's disease, Huntington's disease, Down's Syndrome, Dementia with Lewy Body, or Amyotrophic Lateral Sclerosis (ALS). 
Spoj ili pripravak prema bilo kojem od patentnih zahtjeva 1 do 9 naznačen time da je za uporabu prema zahtjevu 10, pri čemu je bolest Alzheimerova bolest, goveđa spongiformna encefalopatija (GSE), Parkinsonova bolest, Huntingtonova bolest, Downov sindrom, demencija s Lewyjevim tjelešcima, ili amiotrofična lateralna skleroza (ALS).
a mobile suction means for moving along the bottom of the container and suctioning cooling water containing settled particles; 
mobilno sredstvo za usisavanje (22) za pomicanje duž dna (13) spremnika (12) i usisavanje rashladne vode koja sadrži nataložene čestice;
The monoclonal antibody of claim 5, said antibody comprising VH and VL chains having sequences selected from one of the following groups of VH and VL sequences: 
Monoklonalno antitijelo iz patentnog zahtjeva 6 naznačeno time da sadrži VH i VL lance koji imaju sekvencije odabrane iz jedne od sljedećih skupina VH i VL sekvencija:
said reference value of the tension is constant; and 
navedena referentna vrijednost napetosti je konstanta; i -
The blender system of claim 3 wherein the ring comprises at least one wall and a lip coupled to a top of the at least one wall. 
Sustav mješalice prema zahtjevu 3, naznačen time, što obruč (1103) uključuje najmanje jednu stijenku i rub spojen na vrh barem jedne stijenke.
The compound of formula (I') of claim 5 for its use according to claim 5, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, gdje u formuli (I'), R1 je atom vodika, i R2 je atom vodika; hidroksi grupa; ravna ili razgranata C1-C6 alkil grupa; ravna ili razgranata C1-C5 alkoksi grupa; ili ravna ili razgranata C1-C3 tioalkil grupa.
Rw is independently hydrogen or alkyl; 
R" je neovisno vodik ili alkil;
In another embodiment, Compounds of the Invention are compounds of any of Formulae I-XV, wherein A1 is substituted pyridyl having one or two substituents or substituted phenyl having one, two, or three substituents, wherein each substituent is independently selected from the group consisting of halo, cyano, hydroxy, amino, haloalkyl, alkoxy, haloalkoxy, and alkyl. 
Zje -NH-, ili njena farmaceutski prihvatljiva sol ili solvat, i gdje je još poželjnije A' odabran iz grupe koja se sastoji od supstituiranog fenila koji ima jednog ili dva supstituenata 1 supstituiranog piridila koji ima jednog supstituenta, pri čemu je svaki supstituent nezavisno odabran iz grupe koja se sastoji od halo, cijano, hidroksi, amino, haloalkila, alkoksi, haloalkoksi i alkila.
The process according to claim 6, characterized in that the material is dispersed in an aqueous medium subsequent to screening and/or concentrating step e) (step f), preferably in the presence of the at least one lithium ion containing compound. 
Postupak u skladu s patentnim zahtjevom 4, karakteriziran na način da je materijal raspršen u vodenom mediju nakon prosijavanja i/ili koncentriranja u koraku e) (korak f), poželjno u prisustvu barem jedne tvari koja sadrži litijev ion.
Compounds of formula (V) are known or can be prepared using conventional methods. 
OHC If o (V) u prisutnosti pogodnog kondenzacijskog reagensa.
A composition comprising degarelix for use in the treatment of prostate cancer in a subject identified as being at risk for cardiovascular disease. 
Pripravak koji sadrži degareliks za uporabo u liječenju metastatskog stadija raka prostate u subjektu koji ima osnovnu razinu seruma alkalne fosfataze (S-ALP) od 200 IU/L ili više (prije liječenja).
The expression system of claim 10, wherein the encoded polypeptide comprises the amino acid sequence of SEQ ID NO. 
Ekspresijski sustav sukladno zahtjevu 10, naznačen time što kodirani polipeptid sadrži aminokiselinsku sekvencu SEQ ID NO.
Forming micro particles (12), 
formiranja mikročestica (12),
Y is phenyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, each of which is optionally substituted by R9, is 1-4C-alkyl, 1-4C-alkoxy or halogen, or a salt, particularly a pharmaceutically acceptable salt, a tautomer, or a stereoisomer of said compound, or a salt, particularly a pharmaceutically acceptable salt, of said tautomer or said stereoisomer. 
Y je fenil, pirolil, furanil, tienil, tiazolil, oksazolil, tiadiazolil, oksadiazolil, piridinil, pirimidinil, pirazinil ili piridazinil, svaki od navedenih je proizvoljno supstituiran sa R9, R9 je 1-4C-alkil, 1-4C-alkoksi ili halogen, ili sol, naročito farmaceutski prihvatljiva sol, tautomer, ili stereoizomer navedenog spoja, ili sol, naročito farmaceutski prihvatljiva sol navedenog tautomera ili navedenog stereoizomera.
A compound of formula (I) according to claims 1 to 12 for use for preventing and/or inhibiting and/or treating cancer. 
Spoj s formulom (I) prema zahtjevima 1 do 13 naznačen time da je za uporabu za sprječavanje i/ili inhibiciju i/ili liječenje raka.
A pharmaceutical composition comprising a compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski preparat koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
The method according to claim 6 or 7, wherein the neuraminidase inhibitor is oseltamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor oseltamivir.
Recent statistics (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998), indicate that as many as 33 million people worldwide are infected with the virus. In addition to the large number of individuals already infected, the virus continues to spread. 
Nedavna statistika (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998), ukazuje da je širom svijeta 33 milijuna ljudi inficirano ovim virusom, Pored velikog broja osoba koje su već inficirane, virus se nastavlja širiti.
Dilution to give an IL-2 concentration of about 1.1 mg/ml is typical. 
Razrjeđenje da dade IL-2 koncentraciju od oko 1,1 mg/ml je tipično.
the step of isolating said polypeptide; or the step of isolating said polypeptide and determining one or more of cell viability, culture longevity, specific productivity and final recombinant protein titer following isolation; or 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da nadalje obuhvaća određivanje vijabilnosti jedne ili više stanica, dugovječnosti uzgoja, specifične produktivnosti i konačnog titra rekombinantnog proteina nakon izolacije.
iv) optionally at least one wax (D); 
(D) barem jednu gorku tvar.
The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises a light chain variable region sequence comprising the amino acid sequence selected from the group consisting, of SEQ ID NOS: 60, 86, 87 and 89. The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises a non-CDR region of a light chain variable region sequence which is at least 80% identical to the non-CDR region of the light chain variable region sequence selected from the group consisting of SEQ ID NOS: 60, 86, 87 and 89. 
Protutijelo ili njegov fragment sukladno patentnom zahtjevu 1, naznačeno time da, protutijelo ili njegov fragment sadrži sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu amino kiseline odabranu iz skupine koja sadrži SEK ID BR: 45, 46, 47 i 49; ili ne-CDR regiju koja je najmanje 80% istovjetna ne-CDR regiji sekvence promjenjive regije lakog lanca odabrane iz skupine koja sadrži SEK ID BR: 45, 46, 47 ili 49.
In one example, the pain is inflammatory pain, neuropathic pain, or pain associated with cancer, surgery, or bone fracture. 
Spoj za uporabu kako je definiran u zahtjevu 18, naznačen time da bol je upalna bol, neuropatska bol, bol povezana s rakom, bol povezana s operacijom, ili bol povezana s lomom kosti.
A pharmaceutically active component in this connection is a compound that has a therapeutic effect to heal, ameliorate or prevent a particular indication or disease as mentioned herein, preferably cancer diseases, autoimmune disease, allergies or infectious diseases, cardiovascular diseases, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, musculoskeletal disorders, disorders of the connective tissue, neoplasms, immune deficiencies, endocrine, nutritional and metabolic diseases, neural diseases, eye diseases, ear diseases and hereditary diseases. 
Farmaceutski pripravak koji sadrži nukleinsku kiselinu kako je opisana u bilo kojem zahtjevu od 1 do 10 za uporabu za povećanje ekspresije proteina kodiranog s kodirajućom regijom navedene nukleinske kiseline kako je definirano u bilo kojem zahtjevu od 1 do 10 naznačen time da je za liječenje kanceroznih bolesti, zaraznih bolesti, autoimunih bolesti, alergija ili alergijskih bolesti, monogenetskih bolesti, genetskih bolesti, kardiovaskularnih bolesti, neuronskih bolesti, bolesti dišnog sustava, bolesti probavnog sustava, kožnih bolesti, muskuloskeletalnih poremećaja, poremećaja vezivnog tkiva, imunodeficijencija, endokrinih, prehrambenih i metaboličkih bolesti, očnih bolesti ili bolesti uha.
Preferably, the number of additions is 2. 
Broj objave europskog patenta:
A compound of general formula (I) according to claims from 1 or 2, wherein Y is a bivalent radical having the following meaning: straight or branched C2-C6 alkylene, being optionally substituted with -ONO2 or T, wherein T is as defined in claim 1; wherein n is an integer from 0 to 5, and n1 is an integer from 1 to 5; 
Spoj opće formule (I) prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time da Y jest dvovalentni radikal koji ima sljedeće značenje: a) - ravni ili razgranati C»-Cg alkilen koji može biti supstituiran s -ONO, ili T, gdje T jest kao što je definirano u patentnom zahtjevu 1, b) CE) -(CA, nt gdjeje n cijeli brojod Odo 5,an' je cijeli broj od 1 do 5, g)
The transgenic mouse of claim 1, wherein the mouse further comprises in its genome an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with unrearranged human Vλ and Jλ gene segments, and wherein the human Vλ and Jλ gene segments are operably linked to an endogenous mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable sequence fused with a mouse k constant region. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
comprising, after i) and ii): iii) transforming the obtained compound of formula (II) into the compound of formula (I) or an acid addition salt thereof by known methods. 
HR P20181918 T1 sadržeći, nakon 1) 1 1i): iii) pretvaranje dobivenog spoja formule (ID) u spoj formule (1) ili sol kao dodatak kiselini istoga putem poznatih metoda.
introducing a mutation into the nucleotide sequence of the plant cell which encodes the DA1 polypeptide and/or EOD polypeptide or which regulates its expression and regenerating the plant from the mutated cell; 
(a) uvođenje mutacije u nukleotidnu sekvencu biljne stanice, koja kodira polipeptid DA1 i/ili polipeptid EOD, ili koja regulira njegovu ekspresiju, te regeneriranje biljke iz mutirane stanice;
Instead of a manual control 70, the operator would simply enter an input instruction that controller 80 would interpret to be a given application rate. 
Umjesto ručne komande 70, operater će jednostavno unijeti ulaznu uputu koju će kontrolor 80 pročitati kao jednu određenu brzinu nanošenja.
It is rare in adults, but may occur in infants, alcoholics, or the elderly. 
To je rijetko u odraslih, ali može se pojaviti u djece, alkoholičara ili starijih.
The 1-thio-D-glucitol compound, or the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to claim 1 or 2, wherein Ar1 is a heteroarylene group. 
Spoj 1-tio-D-glucitol, ili njegova farmaceutski prihvatljiva sol, ili hidrat spoja ili njegova sol prema zahtjevu 1 ili 2, naznačen time da Ar je heteroarilen skupina.
at least a first and second conductor retainer mounted to and spaced apart along a base member at substantially the pre-determined spacing therebetween, 
najmanje prvi i drugi konduktorski držač (24a, 24b) koji su montirani na temeljnom elementu (20) i razdvojeni su zasebno uzduž istoga,
A pharmaceutical formulation comprising AMG 416 in aqueous solution, wherein the formulation has a pH of 2.0 to 5.0. 
PATENTNI ZAHTJEVI 1. - Farmaceutska formulacija koja sadrži AMG 416 u vodenoj otopini, pri čemu formulacija ima pH od 2.0 do 5.0.
A pharmaceutical dosage form comprising the pharmaceutical composition according to claim 1 . The pharmaceutical dosage form according to claim 7, which contains the first pharmacologically active ingredient in a dose of from 10 to 1,200 ug. 
Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema zahtjevu 7, naznačen time da sadrži prvi farmakološki aktivni sastojak u dozi od 10 do 1,200 ug.
and R2 are the same or different and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aralkyl group which is optionally substituted, wherein when an aromatic hydrocarbon group constituting the aralkyl group is a phenyl group, the phenyl group may form a condensed bicyclic hydrocarbon group, together with the substituent, or R1 and R2 are taken together with the adjacent nitrogen atom to form a saturated heterocyclic group which is optionally substituted; 
R' i R' isti ili različiti a svaki predstavlja atom vodika, alkilnu skupinu koja ima 1 do 6 ugljikovih atoma, ili aralkilnu skupinu koja je po izbru supstituirana, gdje kada skupina aromatskog ugljikovodika sačinjava aralkilnu skupinu koja je fenil skupina, skupina fenila može tvoriti kondenziranu bicikličku ugljikovodičnu skupinu, zajedno sa supstituentom ili su R' i R* uzeti zajedno sa susjednim atomom dušika kako bi oblikovali zasićenu heterocikličku skupinu koja je po izboru supstituirana;
represents hydrogen or C1-4alkyl optionally substituted with C1-4alkoxy; 
R7? predstavlja vodik ili C14 alkil po izboru supstituiran sa Ci4 alkoksi;
In one embodiment of the present invention, the solid support for cultivation of anchorage-dependent cells is made, e.g., of non-woven fibrous matrix bonded to a porous support sheet. 
U drugoj izvedbi ovoga izuma, krute potpore za uzgoj stanica koje potrebuju pričvršćivanje je načinjen od, na primjer ne-utkanog vlaknastog materijala koji je spojen na poroznu potpornu plohu.
The invention provides a composition comprising peptides, which is useful in the prevention or treatment of cat allergy. 
Sastav za uporabu u prevenciji ili liječenju alergije na mačke kod pojedinca po toleranciji sastoji se od polipeptida:
The method as claimed in claim 1, wherein the method further comprises applying a balancing layer on an opposite side of the core, before the applying of heat and pressure, to obtain a balancing layer. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja balansirajućeg sloja (4) na drugu stranu jezgre (3), prije primjene topline i pritiska, da bi se dobio balansirajući sloj.
Preferably, the aerosol generating means includes one or more thermally stable materials which carry one or more aerosol forming substances. 
Poželjno, sredstvo za generiranje aerosola uključuje jedan ili više termički stabilnih materijala koji sadrže jednu ili više supstanci za formiranje aerosola.
The pharmaceutical composition of claim 4, wherein the cholinesterase inhibiting compound is selected from the group consisting of pyridostigmine, donepezil, rivastigmine, galantamine, tacrine, neostigmine, metrifonate, physostigmine, ambenonium, demarcarium, thiaphysovenine, phenserine, edrophonium, cymserine and combinations thereof. 
Farmaceutski sastav, prema zahtjevu 10, naznačen je time da su u njemu inhibirajući spojevi kolinesteraze odabrani iz grupe koja se sastoji od piridostigmina, donepezila, rivastigmina. galantamina, takrina, neostigmina, metrifonata, fizostigmina, ambenonija, demarkarija, tiafizovenina, fenzerina, edrofonija, cimserina i njihovih kombinacija.
A spear gun with a spear drive shaft according to claim 1, characterized in that said ejection member is a piston which during release of the spear gun is driven by the air pressure within a unified air chamber created in the open space between said ejection member, said second barrel and said head member; wherein, 
C - 8,1.c) okružene vanjsko uvezivanje (6 - 6.1). Podvodna puška s pogonskom osovinom harpuna prema zahtjevima 1 do 5, naznačena time, da je pokretanje uređaja je klip (12), koji nakon ekspanzije koplja pomiču tlaka zraka iz zračne komore (A).
The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide consisting of SEQ ID NO: 6. 
Antitijelo koje je specifično protiv MHC/peptidnog kompleksa MHC s peptidom koji se sastoji od SEQ ID br. 14.
represents hydrogen atom 
-R? predstavlja atom vodika
The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a light chain comprising SEQ ID NO: 44 and a heavy chain comprising SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, or SEQ ID NO: 43. 
Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44, 1 teški lanac čiji su sljedovi SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 ili SEQ ID
A cephalosporin derivative represented by Chemical Formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof: 
Derivat cefalosporina predstavljen s Kemijskom Formulom 1, njegov hidrat, njegov solvat, ili njegova farmaceutski prihvatljiva sol: naznačen time da X je CR, N, ili C supstituiran s Cl (C-Cl);
The carrier can be solvent or dispersion medium containing, for example, water, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. 
Podloga može biti otapalo ili disperzija kao medij koji, primjerice, sadrži vodu, po mogućnosti u fiziološki kompatibilnim puferima, poput puferirane Hanksove, Ringerove ili fiziološke otopine, etanol, poliol (primjerice glicerol, propilen-glikol i tekući polietilen-glikol), njihove pogodne smjese, te biljna ulja.
Buffer is oxygenated with 95% O2/5% CO2 for 10 min at 37° C. and pH is adjusted 7.4. 
Bufer se oksidira s 95% O2/5% CO, 10 minuta na 37 stupnjeva C i pH se adaptira s 7.4.
The compound of formula I according to claim 1, wherein R3 is selected from the group consisting of alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl, each of which may be unsubstituted or substituted by one or more substituents selected from group consisting of: -H, alkyl, alkenyl, alkoxy, halogen, -OH, -N3, trifluromethyl, -alkyl-aryl, -O-alkyl-aryl, -CO-aryl, aryl, heterocyclyl, heteroaryl, - CO-heteroaryl, -CO-substituted aryl, -CO-substituted heteroaryl, -CO-O-alkyl, - CO-N-alkyl, -CO-N-aryl. 
alkil, uključujući skupine s nerazgranatim i razgranatim lancem i prstenaste skupine, alkinil, aril, heterociklil i heteroaril, od kojih svaki može biti nesupstituiran ili supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine: -H, -OH, halogen, -CN, -NO2, -COOH, -SH, -CO-C1-6 alkil, -CO-O-C1-6 alkil, -N3, aril, heterociklil, -CO-aril i -CO-heterociklil, se bira iz skupine koju čine:
Our results further show that the progression from a responder to a non-responder status of a patient can be anticipated, thereby allowing implementation of a substantially improved treatment regimen. A method for immuno-detecting an Anti-Drug Antibody (ADA) in a sample, wherein the Drug is a therapeutic antibody directed against a target antigen, the method comprising: verifying the presence of the antigen in the sample; 
Metoda za imunodetekciju protutijela na lijek (ADA) u uzorku, pri čemu je lijek terapijsko protutijelo usmjereno na ciljni antigen, metoda obuhvaća: a) verificiranje prisutnosti antigena u uzorku; b) akoje prisutno, neutraliziranje antigena u uzorku; i €) imunodetekciju prisutnosti količine navedenog ADA u navedenom uzorku.
The compound was prepared from the intermediate obtained in step A above using a similar procedure described in Example 9.8, step B. 
Spoj je pripremljen iz intermedijera iz koraka A uporabom postupka sličnog onome opisanome u Primjeru 9.8, korak B.
wherein drying said methylthioninium chloride pentahydrate Form A to remove excess water and/or solvent is performed by drying in a flow of humid inert gas, wherein the drying conditions are such that the MTC pentahydrate form A is not dehydrated; and wherein the dried methylthioninium chloride pentahydrate Form A has a Form A content of at least 95% based on the total weight of methylthioninium chloride. 
Cc) -metiltioninijklorid se otapa u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25"C, a pritom se organsko otapalo 1 bilo koji višak vode isparava do suhoće krutine; pri čemu se sušenje navedenog metiltioninijklorid (MTC) pentahidrata Oblika A za odstranjivanje viška vode i/ili otapala, provodi putem sušenja u protoku vlažnog inertnog plina, gdje su uvjeti za sušenje takvi, da se MTC pentahidrat Oblika A ne dehidrira; i pritom suhi MTC pentahidrat Oblika A ima sadržaj Oblika A od najmanje 95% na osnovi ukupne mase metiltioninijklorida.